CLINICAL PROOF OF CONCEPT - B-Potent

It is imperative to know the present understanding of its utilization to appraise the

advantages of storing cord blood cells. Every day, new studies have been released,
describing the capacity of cord blood cells to successfully treat different diseases.
How do we realize that a definite scientific promise about the clinical benefit of any
technology is valid? The best proof for virtually any benefit that is asserted is its
own usage by a regulatory agency like the FDA. However, the road to obtain such
approval is expensive and long.Nevertheless effects in clinical studies, or maybe
proof of concept in animal disease models, can offer a good indication on future
potential of certain technology, if obtained with care. In this very long road of
proving clinical effectiveness, the earlier stages of research are usually experiments
completed in test tubes, or"ex vivo", as termed for biological tasks tested in artificial
laboratory arrangement. With the exception of bone marrow transplantation (BMT),
most of the claims exerts possible clinical advantage to cable blood cells are based
now on those very early stages of test tube studies. This can not diminish the
legitimacy of these data that is technological, but should be part of these
considerations in any investment an individual might prefer to perpetrate.Clinical
use of cord blood cells could be divided into two big categories. The foremost is due
to ablated bone marrow, and the second is regeneration of other tissues which are
suffering from numerous diseases. The first, bone marrow transplantation (BMT),
which may be the use of stem cells and progenitor blood cells to rebuild the
damaged tissue accountable for produce all of the blood cells within the body. BMT
is widely used today for treatment of malignancies. The next category is actually a
wide array of diseases which occur more frequently in people, and are related to
degeneration and breakdown of tissues like heart, liver, arteries, bone, neural cells
along with also others. It is believed that category of diseases would be amenable
to treatment for living cells, and especially with stem cells, as a method termed
medicine.Cord blood cells have been used in BMT for almost two years to displace
different sources of stem cells, such as bone marrow and mobilized peripheral
blood. Approximately 20,000 transplants were done compared to about 45,000
transplant performed annual using other cell sources. On the flip side, there are
also advantages, although there are lots of limits to cord blood. The limitations
using cord units per patient or would be gradually over come with the introduction of
new technologies like expansion of stem cells. Still, the issue remains, how
effective is autologous transplant (the individual receives his own cells); when
compared with allogeneic transplant (the individual receives tissues from another
donor, which may be found for example in the general public cord blood banks).For
most, but not for all, hematological malignancies, it is wise to make use of
transplant since the anti tumor effect appears to be stronger combination. If this is
so, why should you store his infant cells? The answer is that for BMT signs, the
cable stem cells may be useful for family members too. In cases like this, that the
combination, along with the advantages of cord arteries, make it using when needed
and worth storing. Furthermore, a donor isn't always easy to find, and so, the stored
cells found such case a fantastic alternative.The most promising future use of cord
blood cells are for its second category of signs, namely for tissue regeneration. This
category covers lots of deteriorating and life threatening diseases such as cardiac
failure, Alzheimer's disease, osteoporosis, muscle degeneration diseases, severe
hepatitis and other diseases for which there are many treatments, but no more
successful cure. The progenitor cells and stem cells which are located in cord blood
have the potential to regenerate damaged cells and thus present new alternative to
treat such diseases.It should be emphasized that now, the majority of the studies
demonstrating results were performed in test tube or animals' laboratory models.
Not many have been through the regulatory pathways of development and non have
been approved by FDA. We can learn in studies conducted by adult stem cells
obtained from other sources like fat cells, peripheral blood, bone marrow along with
others. Taking the potential of stem cells for treating threatening ailments and
diseases is overwhelming, however the actual demonstrate because of their
effectiveness should originate from trials, and that is in its beginning.If cord blood is
considered specifically by us, it's been shown recently that in addition to blood stem
cells, the cord blood feature additional cell inhabitants. Among themcells like
progenitors that can become bone and cartilagecells like progenitors that could form
blood vessels, pluripotent cells that can turn into different cell types, including
muscle, nerves and insulin-producing cells. It was demonstrated that the lymphoid
cells of the cord blood may be useful for immunotherapy of malignant diseases.
Development and research, in addition to clinical studies that will happen years
have to bring such laboratory results. Numbers of high quality books are collecting
always, and the potential is tremendous, and pointing to the right direction.Currently
the Deputy Director of this Sheba Cancer Research Center in Israel. Operating the
Family Cord Blood Bank, Melanoma and Bio Regenerate Inc's Ella Institute for
research and treatment, a start up company adult stem cells technologies and
storage services.Before, the founder and CEO of Gamida Cell Ltd.; CEO of Hadasit
Ltd., the technician transportation business of the Hadassah Medical Center. PhD
from the Weizmann Institute of Science, Rehovot, Israel; Post doc in Stanford
University Medical School.